Supplement Documents for Financial Results Q3 FY12/20

November 10, 2020

Chiome

To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

Agenda

1．Overview of Q3 FY12/20 “Financial results”

2．Overview of Q3 FY12/20 “Operation highlights”

Appendix.

Corporate information

Pipeline information

Overview of
Q3 FY12/20 “Financial results”

Financial results: Profit and Loss

(JPY in millions)

	Q3 FY2019	Q3 FY2020	Increase (decrease)	
Net sales	282	312	29	
Drug Discovery & Development	2	2	0	
Drug Discovery Support	280	309	29	• Growth in business with domestic pharmaceutical companies
COS/SGA	1,451	1,392	(59)	
R&D Expense	1,043	951	(92)	• Decrease in the cost of study drug manufacturing and CRO in CBA-1205 program
Other costs	408	441	33	• Up in material costs due to increased business transactions
Operating Loss	(1,169)	(1,080)	(88)	
Ordinary Loss	(1,177)	(1,087)	(90)	
Net Loss	(1,170)	(1,087)	(82)	

Financial results: Balance Sheet

(JPY in millions)

	As of Dec. 31, 2019	As of Sep. 30, 2020
Current assets	2,561	3,316
(Cash on hand in banks)	2,105	2,881
(Other current assets)	456	435
Non-current assets	247	249
Total assets	2,808	3,565
Current Liabilities	145	378
Non-current liabilities	41	41
Total liabilities	186	420
Total net assets	2,621	3,145
Total liabilities and net assets	2,808	3,565

Overview of
Q3 FY12/20 “Operation highlights”

Business Segment

Drug Discovery and Development Business

To discover and develop novel antibody drugs in-house or in collaboration with a partner up to late pre-clinical stage which enables to prepare data package for IND or early clinical stage in therapeutic areas where high unmet medical needs exist. The drug candidates will be out-licensed to pharmaceutical company under appropriate financial conditions such like upfront, milestone, and royalty payments etc.

Drug Discovery Support business

To provide “fee-for-service” to pharmaceutical and diagnostics company, and academia to support their research works. Main line of this business is 1) to generate a monoclonal antibody for their targets by our proprietary platform, and 2) to express, culture, and purify proteins including antigen and antibody.

Pipeline

Out-Licensed Product

Code	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Clinical Trials	Partner
ADCT-701 (LIV-1205 ADC)	DLK-1	Oncology /ADC				ADC THERAPEUTICS

Pipelines

Project	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Clinical Trials	Status
CBA-1205 (ADCC enhanced)	DLK-1	Oncology				Phase 1
CBA-1535 (Tribody)	5T4×CD3 ×5T4	Oncology				GMP manufacturing
LIV-2008 /2008b	TROP-2	Oncology				Licensing opportunity
BMAA	SEMA3A	DME, Others				SemaThera (Exclusive option agreement)
Discovery PJ (6)	Undisclosed	Oncology infectious/ rare diseases				–

As of Sep.30,2020

Pipeline

CBA-1205 Humanized afucosylated anti-DLK1 antibody	• Dose escalation part of Phase I Study to see safety is on-going well on track at National Cancer Center Hospital. • Implementation of combination study with anticancer drugs and promotion of patent applications.
CBA-1535 Humanized anti 5T4/WAIF1 antibody, multi-specific antibody	• CMC development progressing on schedule. • CTA submission in the UK is expected in the 2nd half of 2021 onwards, however, due to the pandemic of COVID-19 in the UK and Europe, an alternative plan is also in discussion.
LIV-2008 Humanized anti-TROP2 antibody	• Under evaluation for in-licensing by several pharmaceutical companies.
BMAA Humanized anti-Semphorin3A antibody	• Being evaluated by SemaThera Inc. under Collaborative Development License and Exclusive Option Agreement concluded in March 2018.
Discovery PJ	• Proceed preparation and evaluation of ADC for an oncology project in collaboration with potential partners. • To expand pipelines; initiate new joint research with potential partner across the world, leverage Tribody technology.
ADCT-701 Out-Licensed Product	• ADC Therapeutics is continuing preparations for an IND. • Amendment to the License Agreement with ADCT is executed to strengthen Chiome's position in development and licensing.

Pipeline

Amendment to the License Agreement with ADCT to increase the licensing opportunity and business potential of CBA-1205

✓ By ensuring broader rights, Chiome obtains greater flexibility in advancing strategic drug development of anti-DLK-1 antibody, also increase the licensing opportunity and business potential of CBA-1205.



✓ Implementation of combination study with anticancer drugs for CBA-1205 and file patent applications.

Pipeline

A patent application, "Combination of CBA-1205 and Lenvatinib" filed in 2019 is published

Mouse xenograft study: Hep3B hepatoma model
CBA-1205 + Lenvatinib

Patent: WO/2020/204033



Dosing regimen
CBA-1205 : i.p., twice a week x 2 weeks
Lenvatinib: p.o., daily x 5 days a week for 2 weeks



Remarkable tumor regression was observed in combination of CBA-1205 and Lenvatinib in HCC xenograft treatment model.

Drug Discovery Support

Business with pharmaceutical companies, etc.

- Sales increased by 10.5% year-on-year due to growth of business with domestic pharmaceutical companies.
- No impact by COVID-19 on sales in the third quarter.



ADLib ®System

- Inquiries on the human ADLib ® system from pharmaceutical companies increased following the publication of patent and of the paper in the 2nd quarter.
- ADLib ® system is positioned as a key driver in Chiome's business, and therefore, promote further technical improvements.

Financing

➢ Issued series 17th Subscription Rights to Shares to SMBC Nikko Securities Inc. On May. 27, 2020.

<Use of funds>

- to expand pipeline for continuous deliver innovative drugs
- to enhancement of technology platform

Use of funds	Cost (million JPY)	Scheduled period of spending
① Pre-clinical study for a new ADC pipeline and research on discovery projects in oncology and infectious/rare diseases.	1,764	Jul.2020-Dec.2022
②Development of new pipeline by utilizing multispecific antibody generation technology (Tribody™)	250	Jul.2020-Jun.2022
③ Acquisition of new antibody generation technologies and new pipelines.	400	Jan.2021-Dec.2022

< Status of Exercise(as of end of October 2020) >

Total number of shares exercised: 5,998,900/7,000,000 shares (85.7%)

Total value exercised: 1,722 million yen

COVID-19 Business Impact

Despite changes, delays, and postponements of some operations made by the Company and its customers due to the spread of COVID-19, impact on the financial performance in this period was limited.

The Company's performance might be affected if the pandemic continues for a long period of time, causing the Company, research institutes, and business partners to suspend their businesses, close facilities, or delay procedures by authorized agencies in the country or region in which the Company conducts business.

The Company is currently conducting business under a business contingency plan that includes remote working and flexible work shift to cope with the spread of COVID-19.

Appendix. Corporate information

Corporate Overview

Biotech company dedicating to satisfy unmet medical needs



Mission

Shine light on unmet needs.
Bring a brighter future to patients.

Vision

Will become No. 1 biotech venture that discovers and develops antibody drugs for unmet medical needs

Management principle

- Place the highest priority on sound management and credibility and aim to become a corporation that grows with society.
- With creativity and science, develop therapeutic drugs for unmet medical needs, and contribute to the health of patients.
- Achieve successive product pipelines and improvement of corporate value through collaboration with external institutions.

■ Founded:
February 2005

■ Listed on the stock exchange:
December 2011
(Tokyo Stock Exchange Mothers Section)

■ President and Chief Executive Officer:
Shigeru Kobayashi, M.E.

■ Location :
<Head Office and Research Laboratories>
3-12-1Honmachi, Shibuya-ku, Tokyo
<Drug Discovery Laboratories>
2-13-3 Nogawahonchou, Miyamae-ku, Kawasaki-city, Kanagawa

■ Number of Employees :
55 （As of Sep. 30 ,2020)

■ Business :
Chiome Bioscience (4583.T), is a public company leveraging a proprietary monoclonal antibody generating technology, for drug discovery and development, as well as providing drug discovery supports.

Core competence for developing business

Technology Platform (Chiome's mAb Discovery Engine)

Preparation of recombinant proteins

Expression



Recombinant proteins

Membrane proteins

Purification

MAb Generation Platform

ADLib®system



Animal immunization

B cell cloning

Hybridoma

MAb Engineering

Affinity maturation



Functional evaluation

Multi-specific antibody



Lab-scale mAb production

Chiome possesses antibody platforms including its proprietary technology, and extensive know-hows and experiences in protein/antibody engineering to streamline the process of drug discovery.

This enables us to contribute in

Drug Discovery and Development

Development of therapeutic drug and diagnostic agent

Drug Discovery Support

Contract service for drug discovery

Revenue Model

Drug development process and Chiome's revenue model



Drug Discovery

Revenues by licensing-out patents of pipeline product and drug candidates to pharmaceutical companies.



Drug Discovery Support

Revenues by providing drug discovery supporting services to pharmaceutical and diagnostics company, and academia.

Contract service

<Key business accounts>

Name of accounts	Entering date
Chugai Pharmaceutical Co., Ltd.	Jun. 2011
Chugai Pharmabody Research Pte. Ltd.	Aug. 2012
Mitsubishi Tanabe Pharma Corporation Tanabe Research Laboratories U.S.A., Inc.	Dec. 2016
Ono Pharmaceutical Co., Ltd.	Oct. 2018
Kyowa Kirin Co., Ltd.	July 2019

Our stability and growth potential

Core technology will sustain continuous development of therapeutic antibody while offering higher quality of service



Appendix. Pipeline information

Pipeline -Out-Licensed-

ADCT-701* (Humanized anti-DLK1 antibody ADC)

- ✓ An Antibody Drug Conjugate (ADC) form of LIV-1205 that was licensed out to Switzerland-based ADC Therapeutics SA in September 2017.
- ✓ ADCT has completed pharmacology and toxicology studies required for an IND submission and is continuing preparations for an Investigational New Drug Application (IND).

*Chiome granted ADCT a worldwide exclusive license with a right to sublicense, develop, manufacture, and commercialize an PBD-based ADC format of LIV-1205, which is coded “ADCT-701”.

ADC THERAPEUTICS

Pipeline -In-house program-

CBA-1205（Humanized afucosylated anti-DLK1 antibody）

First in class

- ✓ A humanized antibody generated by hybridoma technology in Livtech which Chiome acquired in 2015.
- ✓ Therapeutic Area : Liver cancer, lung cancer, neuroblastoma etc.
- ✓ Patent : Granted in Japan, US, Europe, China etc.
- ✓ Unmet needs that we should satisfy : Providing new therapeutics for highly malignant tumors without effective therapeutic drugs including hepatocellular carcinoma.

CBA-1535（Humanized anti 5T4 antibody, multi-specific antibody）

- ✓ CBA-1535 is a T-cell engager, trispecific antibody, directed against the 5T4 tumor antigen, a protein found on various solid tumors and is thought to be involved in metastasis.
- ✓ Therapeutic Area ：Malignant mesothelioma, small cell lung cancer, non small cell lung cancer, TNBC etc.
- ✓ Patent : Granted in Japan and UK, Pending in US, Europe etc.



Pipeline -In-house developed-

LIV-2008（Humanized anti-TROP2 antibody）

- ✓ LIV-2008 is a humanized monoclonal antibody targeting cell surface antigen "TROP-2" which is overexpressed in breast cancer, colon cancer, lung cancer and several types of solid cancers and also expected to play a key role in the proliferation of cancer cells.
- ✓ Therapeutic Area : Breast cancer (TNBC), lung cancer, colorectal cancer etc.
- ✓ Patent : Granted in Japan, US, EU, China etc.

BMAA（Humanized anti-Semaphorin3A antibody）

First in class

- ✓ A humanized antibody generated using the ADLib® System.
- ✓ Chiome has granted SemaThera Inc. an exclusive option right to obtain a worldwide exclusive license to develop the antibody as a therapeutic and/or diagnostic agent.
- ✓ Therapeutic Area : Diabetic macular edema (DME)
- ✓ Patent : Granted in Japan, US and Europe etc.


Shine light on unmet needs.
Bring a brighter future to patients.
To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs

Disclaimer

- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.

- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.